TV News LIES

Wednesday, Jan 18th

Last update05:20:13 AM GMT

You are here News Health Study outcome won't sway company on eye drug

Study outcome won't sway company on eye drug

E-mail Print PDF

What does a company do when there's anecdotal evidence that two of its drugs are equally effective in treating a leading cause of blindness in the elderly, one costing patients $60 per treatment and the other $2,000?

In the case of Genentech Inc., nothing.

The company declined to seek federal approval for the cheaper drug, Avastin, to treat the wet form of age-related macular degeneration. Nor would it help finance _ or cooperate with _ a National Eye Institute study comparing the effectiveness and safety of Avastin, a cancer drug, and the more expensive eye drug, Lucentis.

More...


Most Recent Related Stories...


18 Million People Could Lose Insurance In First Year After Partial Obamacare Repeal

18 million people could lose health insuranceA partial repeal of Obamacare could leave 18 million people who have insurance today with no...

Bo Jackson opens up about football's CTE risk

Bo JacksonMost scientists believe that CTE, a progressive degenerative brain disease, is associated with repeated blows to...

Obamacare Rallies Around the Country

Obamacare ralliesSupporters of the Affordable Care Act gathered to protest the health care law’s repeal in rallies...

Desmond Tutu Joins Advocates To Call For Right To Assisted Death

Desmond Tutu calls for assisted deathDesmond Tutu, South Africa's former Anglican archbishop and a Nobel Peace Prize laureate, recently celebrated his...
 
America's # 1 Enemy
Tee Shirt
& Help Support TvNewsLIES.org!
TVNL Tee Shirt
 
TVNL TOTE BAG
Conserve our Planet
& Help Support TvNewsLIES.org!
 
Get your 9/11 & Media
Deception Dollars
& Help Support TvNewsLIES.org!
 
The Loaded Deck
The First & the Best!
The Media & Bush Admin Exposed!